Cystic Fibrosis Expanded Screen - CFvantage

CFvantage® Cystic Fibrosis Expanded Screen

Clinical Significance

The CFvantage® Cystic Fibrosis Expanded Screen analyzes 155 mutations that have been proven to cause Cystic Fibrosis. This panel includes the 23 mutations recommended by the American College of Obstetricians and Gynecologists (ACOG) for screening of all child bearing age women. ACOG also recommends that patients with a family history of Cystic Fibrosis, pregnant women with ultrasound finding that indicate an increased risk of Cystic Fibrosis (echogenic bowel or dilated loops of the bowl), and males with a family history of infertility should be offered this screen.

a ACMG/ACOG-recommended mutation.1
b The variants 5T/7T/9T are included as needed (see Interpretive Information). 5T/7T/9T may be of clinical significance in congenital absence of the vas deferens (CAVD) and other disorders.